Critical Review: Climb Bio (CLYM) vs. The Competition

Climb Bio (NASDAQ:CLYM) is one of 1,060 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Climb Bio to similar companies based on the strength of its dividends, analyst recommendations, risk, profitability, institutional ownership, earnings and valuation.

Profitability

This table compares Climb Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-42.21%	-41.39%
Climb Bio Competitors	-3,590.11%	-276.96%	-39.10%

Institutional & Insider Ownership

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 3.2% of Climb Bio shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Climb Bio and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Climb Bio	N/A	-$35.12 million	-1.14
Climb Bio Competitors	$2.20 billion	$150.62 million	-5.46

Climb Bio’s peers have higher revenue and earnings than Climb Bio. Climb Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Climb Bio has a beta of -0.4, indicating that its share price is 140% less volatile than the S&P 500. Comparatively, Climb Bio’s peers have a beta of 3.71, indicating that their average share price is 271% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Climb Bio and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	0	0	1	1	3.50
Climb Bio Competitors	7744	21123	48811	1224	2.55

Climb Bio currently has a consensus target price of $10.00, indicating a potential upside of 313.22%. As a group, “Pharmaceutical preparations” companies have a potential upside of 184.71%. Given Climb Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Climb Bio is more favorable than its peers.

Summary

Climb Bio beats its peers on 7 of the 13 factors compared.

About Climb Bio

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.